{
    "Overall_score": {
        "Correlation": 8,
        "Sentiment": 7,
        "Importance": 7,
        "Impact": 6,
        "Duration": 5,
        "Virality": 4,
        "Source_Score": 6,
        "Specificity": 7,
        "Sector_Spread": 6,
        "Tech_Mentions": 3
    },
    "Each_item": [
        {
            "News_content": "@pharmamaven amazing run you had over the last year $CELG $ACAD $TGTX $ZIOP $CRMD $OMED",
            "Correlation": 7,
            "Sentiment": 8,
            "Importance": 4,
            "Impact": 5,
            "Duration": 3,
            "Virality": 6,
            "Source_Score": 5,
            "Specificity": 4,
            "Sector_Spread": 8,
            "Tech_Mentions": 1
        },
        {
            "News_content": "$CELG/Inhibrx anti-CD47 mAb CC-90002 PhI trial finally posted (N=100) $TRIL",
            "Correlation": 9,
            "Sentiment": 7,
            "Importance": 8,
            "Impact": 7,
            "Duration": 6,
            "Virality": 3,
            "Source_Score": 7,
            "Specificity": 9,
            "Sector_Spread": 4,
            "Tech_Mentions": 8
        },
        {
            "News_content": "Celgene's REVLIMID approved by the European Commission for treatment of adults with untreated multiple myeloma. ($CELG)",
            "Correlation": 10,
            "Sentiment": 9,
            "Importance": 9,
            "Impact": 8,
            "Duration": 7,
            "Virality": 5,
            "Source_Score": 8,
            "Specificity": 10,
            "Sector_Spread": 3,
            "Tech_Mentions": 2
        }
    ]
}